Jorge Millán Pascual

Dr. Jorge Millán Pascual

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
DGDavid García-Azorín
David García-Azorín
MAMaria Jose Abenza-Abildua
Maria Jose Abenza-Abildua
MEMaria Elena Erro
Maria Elena Erro
SFSantiago Fernández Fernández
Santiago Fernández Fernández
JGJuan Carlos García-Moncó
Juan Carlos García-Moncó
VCVictoriano Romero Cantero
Victoriano Romero Cantero

1 September 2021 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
PDF file
GAGeorgina Arrambide
Georgina Arrambide
MLMiguel Ángel Llaneza-González
Miguel Ángel Llaneza-González
LFLucienne Costa França
Lucienne Costa França
VMVirginia Meca-Lallana
Virginia Meca-Lallana
EDEva Fernández- Díaz
Eva Fernández- Díaz
JMJOSE EUSTASIO MECA-LALLANA
JOSE EUSTASIO MECA-LALLANA
Objective To understand COVID-19 characteristics in people with multiple sclerosis (MS) and identify high-risk individuals due to their immunocompromised state resulting from the use of disease-modifying treatments. Methods Retrospective and multicenter registry in patients with MS with suspected or confirmed COVID-19 diagnosis and available disease course (mild = ambulatory; severe = hospitalization; and critical = intensive care unit/death). Cases were analyzed for associations between MS characteristics and COVID-19 course and for identifying risk factors for a fatal outcome. Results Of the 326 patients analyzed, 120 were cases confirmed by real-time PCR, 34 by a serologic test, and 205 were suspected. Sixty-nine patients (21.3%) developed severe infection, 10 (3%) critical, and 7 (2.1%) died. Ambulatory patients were higher in relapsing MS forms, treated with injectables and oral first-line agents, whereas more severe cases were observed in patients on pulsed immunosuppressors and critical cases among patients with no therapy. Severe and critical infections were more likely to affect older males with comorbidities, with progressive MS forms, a longer disease course, and higher disability. Fifteen of 33 patients treated with rituximab were hospitalized. Four deceased patients have progressive MS, 5 were not receiving MS therapy, and 2 were treated (natalizumab and rituximab). Multivariate analysis showed age (OR 1.09, 95% CI, 1.04–1.17) as the only independent risk factor for a fatal outcome. Conclusions This study has not demonstrated the presumed critical role of MS therapy in the course of COVID-19 but evidenced that people with MS with advanced age and disease, in progressive course, and those who are more disabled have a higher probability of severe and even fatal disease.

25 October 2012 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
JPJorge Millán Pascual
Jorge Millán Pascual
LTLaura Turpín-Fenoll
Laura Turpín-Fenoll
PSPablo Del Saz-Saucedo
Pablo Del Saz-Saucedo
IRIgnacio Rueda-Medina
Ignacio Rueda-Medina
SNSantiago Navarro-Muñoz
Santiago Navarro-Muñoz

29 January 2022 in Antioxidants
Verified
Journal Article
Open access
PDF file
Felix Javier Jiménez JiménezFelix Javier Jiménez Jiménez
Felix Javier Jiménez Jiménez
PPPedro Ayuso Parejo
Pedro Ayuso Parejo
HAHortensia Alonso-Navarro
Hortensia Alonso-Navarro
MCMarisol Calleja
Marisol Calleja
MDMónica Díez-Fairén
Mónica Díez-Fairén
EMELENA GARCIA MARTIN
ELENA GARCIA MARTIN
Increased brain and serum zinc levels in patients with idiopathic restless legs syndrome (idiopathic RLS or iRLS) were described when compared with controls, suggesting a possible role of zinc in the pathogenesis of this disease. However, serum magnesium, calcium, manganese, iron, and copper levels of RLS patients were similar to controls, suggesting a specific impairment of zinc-dependent metabolism in RLS. The aim of this study is to assess the serum concentrations of trace elements involved in oxidative stress or causing peripheral nerve toxicity in a large series of patients with iRLS and controls. We determined serum levels of iron, copper, manganese, zinc, magnesium, selenium, calcium, aluminium, lead, cadmium, arsenic and mercury in 100 patients diagnosed with iRLS and in 110 age- and sex-matched controls using Inductively Coupled Plasma Mass Spectrometry. Serum copper, magnesium, selenium, and calcium concentrations were significantly higher in RLS patients than in controls. These differences were observed both in men and women. There were no major correlations between serum trace metal concentrations and age at onset of RLS or RLS severity, nor was there any association with a family history of RLS or drug response. This study shows an association between increased serum concentrations of copper, magnesium, selenium, and calcium with RLS in a Spanish Caucasian population and does not confirm the previously reported increase in serum zinc concentrations in patients suffering from this disease, suggesting that the different accuracy of the analytical methods used could have influenced the inconsistent results found in the literature.

23 April 2014 in BMC Neurology
Verified
Journal Article
Open access
PDF file
Jose AgundezJose Agundez
Jose Agundez
EMELENA GARCIA MARTIN
ELENA GARCIA MARTIN
CMCarmen Martínez
Carmen Martínez
JBJulián Benito-León
Julián Benito-León
JPJorge Millán Pascual
Jorge Millán Pascual
Felix Javier Jiménez JiménezFelix Javier Jiménez Jiménez
Felix Javier Jiménez Jiménez
A possible role of oxidative stress in the pathogenesis of multiple sclerosis (MS) and in experimental autoimmune encephalomyelitis has been suggested. The detoxification enzyme NAD(P)H dehydrogenase, quinone 1 (NQO1) has been found up-regulated in MS lesions. A previous report described an association between the SNP rs1800566 in the NQO1 gene and the risk for MS in the Greek population. The aim of this study was to replicate a possible influence of the. SNP rs1800566 in the NQO1 gene in the risk for MS in the Spanish Caucasian population.

1 March 2025 in Neurology Neuroimmunology & Neuroinflammation
Verified
Journal Article
Open access
JVJavier Villacieros-Álvarez
Javier Villacieros-Álvarez
CECarmen Espejo
Carmen Espejo
GAGeorgina Arrambide
Georgina Arrambide
ADAlessandro Dinoto
Alessandro Dinoto
PMPatricia Mulero
Patricia Mulero
RMRomain Marignier
Romain Marignier
To characterize the serum cytokine profile in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) at onset and during follow-up and assess their utility for predicting relapses and disability. This retrospective multicentric cohort study included patients aged 16 years and older meeting MOGAD 2023 criteria, with serum samples collected at baseline (≤3 months from disease onset) and follow-up (≥6 months from the baseline), and age-matched and time to sampling-matched patients with multiple sclerosis (MS). Eleven cytokines were assessed using the ELLA system. Data comparisons and statistical analyses between cytokine levels and clinical outcomes were performed. Eighty-eight patients with MOGAD and 32 patients with MS were included. Patients with MOGAD showed higher IL6 (p = 0.036), IL8 (p = 0.012), and IL18 (p = 0.026) baseline levels compared with those with MS, in non-optic neuritis (ON) presentations. BAFF values increased over time, especially in patients with MOGAD treated with anti-CD20 (p = 0.002). Baseline BAFF, CXCL10, IL10, and IL8 levels correlated with disease severity at MOGAD onset (all p < 0.05). Finally, higher baseline BAFF levels predicted lower risk of relapses (hazard ratio 0.41 [0.19; 0.89], p = 0.024). This study suggests a proinflammatory Th17-dominant profile in non-ON MOGAD patients, with a novel finding of a potential protective role of BAFF on relapses. These results shed new light on the pathogenesis of MOGAD, potentially guiding therapeutic decisions.